Sonoma Pharmaceuticals, Inc. Contracts & Agreements

Amendment No. 1 to Distribution Agreement, dated October 17, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (Filed With SEC on October 22, 2024)

Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (Filed With SEC on August 21, 2024)

Amendment No. 1 to Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated March 8, 2024 (Filed With SEC on March 8, 2024)

Offer letter to Jerome Dvonch dated February 7, 2024 (Filed With SEC on February 8, 2024)

Offer letter to John Dal Poggetto dated February 7, 2024 (Filed With SEC on February 8, 2024)

License and Distribution Agreement, dated January 5, 2024, by and between Sonoma Pharmaceuticals, Inc. and NovaBay Pharmaceuticals, Inc (Filed With SEC on January 9, 2024)

Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated December 15, 2023 (Filed With SEC on December 18, 2023)

Boulder Lease Agreement between the Company and Westland Development Services, Inc., dated February 19, 2021 (Filed With SEC on November 13, 2023)

First Amendment to the Lease between the Company and Westland Development Services, Inc, dated June 21, 2023 (Filed With SEC on November 13, 2023)

Form of Placement Agency Agreement (Filed With SEC on October 13, 2023)

Form of Securities Purchase Agreement (Filed With SEC on October 13, 2023)

Offer letter to John Dal Poggetto dated July 11, 2023 (Filed With SEC on July 14, 2023)

Consulting Agreement, by and between the Company and Jerome Dvonch Consulting, LLC, effective August 15, 2023 (Filed With SEC on July 14, 2023)

Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated June 16, 2023 (Filed With SEC on June 21, 2023)

Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated June 16, 2023 (Filed With SEC on June 21, 2023)

Consulting Agreement, by and between the Company and Jerome Dvonch, dated April 7, 2023 (Filed With SEC on April 13, 2023)

Amendment to At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated February 24, 2023 (Filed With SEC on February 24, 2023)

Exclusive Distribution and Supply Agreement, dated January 26, 2023, by and between Sonoma Pharmaceuticals, Inc. and Daewoong Pharmaceutical Co., Ltd (Filed With SEC on January 31, 2023)

SONOMA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM AND STOCK OWNERSHIP GUIDELINES Revised by the Board of Directors on December29, 2022 (Filed With SEC on December 30, 2022)

At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated December 23, 2022 (Filed With SEC on December 23, 2022)

Offer letter to Chad White dated September 8, 2022 (Filed With SEC on October 7, 2022)

Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated July 22, 2022 (Filed With SEC on July 22, 2022)

Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated July 22, 2022 (Filed With SEC on July 22, 2022)

Non-Exclusive Distribution and Supply Agreement between Sonoma Pharmaceuticals, Inc. and Salus Medical, LLC dated January 19, 2022 (Filed With SEC on January 20, 2022)

Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022 (Filed With SEC on January 20, 2022)

Exclusive License and Distribution Agreement between the Company and Dyamed Biotech Pte, Ltd., dated November 4, 2021 (Filed With SEC on November 9, 2021)

At-The-Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated July 30, 2021 (Filed With SEC on July 30, 2021)

Employment Agreement by and between the Company and Amy Trombly, dated July 1, 2021 (Filed With SEC on July 6, 2021)

Employment Agreement by and between the Company and Jerry Dvonch, dated July 1, 2021 (Filed With SEC on July 6, 2021)

Employment Agreement by and between the Company and Bruce Thornton, dated July 1, 2021 (Filed With SEC on July 6, 2021)

Exclusive Supply and Distribution Agreement between the Company and EMC Pharma, LLC, dated March 26, 2021 (Filed With SEC on March 31, 2021)

Addendum to Employment Agreement with Amy Trombly, dated January 4, 2020 (Filed With SEC on January 8, 2021)

Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Gabriel Science, LLC, effective December 14, 2020 (Filed With SEC on December 17, 2020)

Exclusive Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc., effective December 4, 2020 (Filed With SEC on December 10, 2020)

Offer letter J. Dvonch dated August 10, 2020 (Filed With SEC on September 11, 2020)

Amendment No. 1 to the Consulting Agreement between the Company and TechCXO, LLC dated September 10, 2020 (Filed With SEC on September 11, 2020)

Licensing Agreement between Sonoma Pharmaceuticals, Inc. and Microsafe Group, effective July 27, 2020 (Filed With SEC on August 6, 2020)

Amendment No. 9 to Office Lease Agreement between the Company and SSCOP Properties LLC, dated June 20, 2020 (Filed With SEC on July 10, 2020)

Woodstock Lease Agreement between the Company and Fowler Crossing Partners, LP, dated October 1, 2018 (Filed With SEC on July 10, 2020)

Asset Purchase Agreement between Sonoma Pharmaceuticals, Inc. and Infinity Labs SD Inc., dated June 24, 2020 (Filed With SEC on June 29, 2020)

Separation and Release Agreement between the Company and Dr. Robert Northey, dated May 29, 2020 (Filed With SEC on June 4, 2020)

Consulting Agreement between the Company and Dr. Robert Northey, dated May 30, 2020 (Filed With SEC on June 4, 2020)

License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020 (Filed With SEC on May 26, 2020)

Consulting Agreement between the Company and TechCXO, LLC effective April 14, 2020 (Filed With SEC on April 20, 2020)

Mutual Separation and Release Agreement between the Company and John Dal Poggetto, dated April 14, 2020 (Filed With SEC on April 20, 2020)

Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and Microsafe Group, DMCC (Filed With SEC on February 27, 2020)

Employment Agreement between Sonoma Pharmaceuticals, Inc. and Amy Trombly, effective December 26, 2019 (Filed With SEC on December 31, 2019)

Form of Placement Agent Warrant granted to Dawson James Securities, Inc. in connection with the November 2019 public offering (Filed With SEC on November 29, 2019)

Placement Agency Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Dawson James Securities, Inc., as representative, dated November 26, 2019 (Filed With SEC on November 29, 2019)

Employment Agreement between Sonoma Pharmaceuticals, Inc. and Amy Trombly, effective September 25, 2019 (Filed With SEC on October 15, 2019)

Employment Agreement between Sonoma Pharmaceuticals, Inc. and John Dal Poggetto, effective September 25, 2019 (Filed With SEC on October 15, 2019)

Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd (Filed With SEC on May 22, 2019)

Separation and Mutual Release between Sonoma Pharmaceuticals, Inc. and Jim Schutz, dated December 13, 2018 (Filed With SEC on December 14, 2018)

Separation and Mutual Release between Sonoma Pharmaceuticals, Inc. and Robert E. Miller, dated December 13, 2018 (Filed With SEC on December 14, 2018)

Employment Agreement between Sonoma Pharmaceuticals, Inc. and Frederick Sandford, effective December 11, 2018 (Filed With SEC on December 14, 2018)

Form of Series C Warrant (Filed With SEC on November 21, 2018)

Form of Unit Purchase Option (Filed With SEC on November 21, 2018)

Placement Agency Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Dawson James Securities, Inc., as representative, dated November 16, 2018 (Filed With SEC on November 21, 2018)

Warrant Agency Agreement by and among Sonoma Pharmaceuticals, Inc. and Computershare, Inc. and Computershare Trust Company, N.A., dated November 21, 2018 (Filed With SEC on November 21, 2018)

Form of Series C Warrant (Filed With SEC on November 16, 2018)

Form of Representative's Unit Purchase Option (Filed With SEC on November 16, 2018)

Form of Placement Agency Agreement (Filed With SEC on November 16, 2018)

Form of Warrant Agency Agreement (Filed With SEC on November 16, 2018)

Form of Series C Warrant (Filed With SEC on November 7, 2018)

Commercial Lease (Georgia office) by and between Sonoma Pharmaceuticals, Inc. and PMR Holdings, LLC, dated May 1, 2018 (Filed With SEC on June 26, 2018)

Exclusive License and Distribution Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and EMS S.A. dated June 4, 2018 (Filed With SEC on June 5, 2018)

Form of Placement Agent Warrant granted to Dawson James Securities, Inc. and The Benchmark Company, LLC in connection with the March 2, 2018 public offering, dated March 6, 2018 (Filed With SEC on March 6, 2018)

Placement Agency Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Dawson James Securities, Inc. as representative of the placement agents, dated March 2, 2018 (Filed With SEC on March 6, 2018)

Securities Purchase Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Montreux Equity Partners V, L.P., dated March 1, 2018 (Filed With SEC on March 6, 2018)

At Market Issuance Sales Agreement, dated December 8, 2017, by and between Sonoma Pharmaceuticals, Inc. and B. Riley FBR, Inc (Filed With SEC on December 8, 2017)

Specimen Common Stock Certificate (Filed With SEC on June 28, 2017)

Master Vendor Agreement by and between Sonoma Pharmaceuticals, Inc. and PetSmart Home Office, Inc., dated November 21, 2016 (Filed With SEC on June 28, 2017)

Distribution Agreement by and between Sonoma Pharmaceuticals, Inc. and G. Pohl-Boskamp GmbH & Co. KG, dated April 13, 2016 (Filed With SEC on June 28, 2017)

Amendment No. 8 to Office Lease Agreement by the between Oculus Innovative Sciences, Inc. and SSCOP Properties LLC, dated June 23, 2016 (Filed With SEC on June 28, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on February 17, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on December 1, 2016)

BACKGROUND (Filed With SEC on October 31, 2016)

SECTION 382 RIGHTS AGREEMENT dated as of October 18, 2016 between OCULUS INNOVATIVE SCIENCES, INC. and COMPUTERSHARE INC., as Rights Agent (Filed With SEC on October 21, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on July 29, 2016)

COMMON SHARE PURCHASE WARRANT OCULUSINNOVATIVE SCIENCES, INC. (Filed With SEC on June 21, 2016)

EXCLUSIVE SALES AND DISTRIBUTION AGREEMENT (Filed With SEC on March 23, 2016)

UNDERWRITING AGREEMENT By and between OCULUS INNOVATIVE SCIENCES, INC. and DAWSON JAMES SECURITIES, INC., asRepresentative of the Several Underwriters (Filed With SEC on March 18, 2016)

OCULUS INNOVATIVE SCIENCES, INC. and COMPUTERSHAREINC. and ComputershareTRUST COMPANY, N.A. WARRANT AGREEMENT Dated as of March 18, 2016 (Filed With SEC on March 18, 2016)

AMENDMENT NO. 1 TO SLA BRANDS, INC. SALES REPRESENTATION CONTRACT (Filed With SEC on February 16, 2016)

SECURITIES PURCHASE Follow-UpAGREEMENT (Filed With SEC on March 16, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 16, 2015)

SLA Brands, Inc. SALES REPRESENTATION CONTRACT (Filed With SEC on March 2, 2015)

OCULUS INNOVATIVE SCIENCES, INC. UNDERWRITING AGREEMENT January 20, 2015 (Filed With SEC on January 26, 2015)

OCULUS INNOVATIVE SCIENCES, INC. and COMPUTERSHAREINC. and ComputershareTRUST COMPANY, N.A. WARRANT AGREEMENT Dated as of January 20, 2015 (Filed With SEC on January 26, 2015)

COMMON STOCK PURCHASE WARRANT OCULUSINNOVATIVE SCIENCES, INC. (Filed With SEC on January 26, 2015)

OCULUS INNOVATIVE SCIENCES, INC. UNDERWRITING AGREEMENT January ___,2015 (Filed With SEC on January 20, 2015)

OCULUS INNOVATIVE SCIENCES, INC. And COMPUTERSHAREINC. And ComputershareTRUST COMPANY, N.A. WARRANT AGREEMENT Dated as of [________], 2015 (Filed With SEC on January 16, 2015)

OCULUS INNOVATIVE SCIENCES, INC. UNDERWRITING AGREEMENT [____________], 2015 (Filed With SEC on January 13, 2015)

OCULUS INNOVATIVE SCIENCES, INC. And COMPUTERSHAREINC. And ComputershareTRUST COMPANY, N.A. WARRANT AGREEMENT Dated as of [________], 2015 (Filed With SEC on January 13, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 12, 2015)

OCULUS INNOVATIVE SCIENCES, INC. UNDERWRITING AGREEMENT [____________], 2015 (Filed With SEC on January 7, 2015)

OCULUS INNOVATIVE SCIENCES, INC. and COMPUTERSHAREINC. and ComputershareTRUST COMPANY, N.A. WARRANT AGREEMENT Dated as of [_____________], 2015 (Filed With SEC on January 7, 2015)

COMMON STOCK PURCHASE WARRANT OCULUSINNOVATIVE SCIENCES, INC. (Filed With SEC on January 7, 2015)

LEASE AGREEMENT BY AND BETWEEN 2500 YORK, L.P. ("Landlord") AND OCULUS INNOVATIVESCIENCES, INC. ("Tenant") FOR PROPERTYAT Suite 130, FirstFloor 2500 York Road Jamison, PA 18929... (Filed With SEC on August 12, 2014)

OCULUS INNOVATIVE SCIENCES, INC. Common Stock (par value $0.0001 per share) At-the-Market Issuance Sales Agreement (Filed With SEC on April 2, 2014)

SERIES A COMMON STOCK PURCHASE WARRANT oculusinnovative sciences, inc. (Filed With SEC on February 26, 2014)

SERIES B COMMON STOCK PURCHASE WARRANT oculusinnovative sciences, inc. (Filed With SEC on February 26, 2014)

COMMON STOCK PURCHASE WARRANT oculusinnovative sciences, inc. (Filed With SEC on February 26, 2014)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on February 26, 2014)

COMMON STOCK PURCHASE WARRANT oculusinnovative sciences, inc. (Filed With SEC on February 14, 2014)

FUNDING AGREEMENT (Filed With SEC on February 6, 2014)

AMENDED SEPARATION AGREEMENT (Filed With SEC on February 6, 2014)

AMENDMENT NO. 3 TO LICENSE AND SUPPLYAGREEMENT (Filed With SEC on February 6, 2014)

AMENDMENT NO. 1 TO SHARED SERVICES AGREEMENT (Filed With SEC on February 6, 2014)

FormOF SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 6, 2013)

AMENDMENT NO. 1 TO LICENSE AND SUPPLY AGREEMENT (Filed With SEC on November 19, 2013)

AMENDMENT NO. 2 TO LICENSE AND SUPPLYAGREEMENT (Filed With SEC on November 19, 2013)

Oculus Innovative Sciences, Inc. 1129 North McDowell Boulevard Petaluma, CA 94954 (Filed With SEC on November 19, 2013)

Licenseand Supply Agreement (Filed With SEC on September 24, 2013)

SEPARATION AGREEMENT (Filed With SEC on August 8, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on June 25, 2013)

Licenseand Supply Agreement (Filed With SEC on June 7, 2013)

SHARED SERVICES AGREEMENT (Filed With SEC on June 7, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on March 22, 2013)

7,500,000Shares of Common Stock OCULUSINNOVATIVE SCIENCES, INC. UNDERWRITING AGREEMENT (Filed With SEC on March 7, 2013)

FORM OF REPRESENTATIVE’S WARRANT AGREEMENT (Filed With SEC on March 7, 2013)

ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIALMULTI-TENANT LEASE-GROSS BY AND BETWEEN KCMKCPROPERTIES, LLP, AS LESSOR, AND OCULUS INC. A DELAWARE CORPORATION, AS LESSEE FOR THE... (Filed With SEC on November 8, 2012)

AMENDMENTTO LEASE DATED AUGUST 30, 2012 BY AND BETWEEN KCKMC PROPERTIES, LLC ("LESSOR") AND OCULUS, INC., A DELAWARE CORPORATION("LESSEE") FOR THEPROPERTY LOCATED AT 304565TH... (Filed With SEC on November 8, 2012)

AMENDMENTNO. 7 TO LEASE (Filed With SEC on November 8, 2012)

STOCKPURCHASE AGREEMENT (Filed With SEC on November 1, 2012)

Venture Lending & Leasing V, Inc. 104 La Mesa Dr., Suite 102 Portola Valley, CA 94028 October 30, 2012 (Filed With SEC on November 1, 2012)

Venture Lending & Leasing VI, Inc. 104 La Mesa Dr., Suite 102 Portola Valley, CA 94028 October 30, 2012 (Filed With SEC on November 1, 2012)

License,Exclusive Distribution and Supply Agreement (Filed With SEC on August 15, 2012)

ExclusiveDistribution and Supply Agreement (Filed With SEC on August 15, 2012)

COLLABORATION AGREEMENT (Filed With SEC on August 3, 2012)

FORM OF COMMON STOCK PURCHASE WARRANT oculusinnovative sciences, inc. (Filed With SEC on April 25, 2012)

OCULUS INNOVATIVE SCIENCES, INC. CERTIFICATE OF DESIGNATIONOF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A 0% CONVERTIBLEPREFERRED STOCK PURSUANT TO SECTION 151OF THE DELAWARE... (Filed With SEC on April 25, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 25, 2012)

WARRANT TO PURCHASE SHARES OF COMMON STOCK OF OCULUS INNOVATIVE SCIENCES, INC. (Void after November 30, 2018) _______________________________________________ (Filed With SEC on February 10, 2012)

WARRANT TO PURCHASE SHARES OF COMMON STOCK OF OCULUS INNOVATIVE SCIENCES, INC. (Void after November 30, 2018) _______________________________________________ (Filed With SEC on November 3, 2011)

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT EXCLUSIVE COVER PAGE (Filed With SEC on November 3, 2011)

DISTRIBUTION AGREEMENT (Filed With SEC on August 4, 2011)

LOAN AND SECURITY AGREEMENT Dated as of June 29, 2011 between OCULUS INNOVATIVE SCIENCES, INC., a Delaware corporation, as Borrower, and VENTURE LENDING & LEASING VI, INC., a... (Filed With SEC on July 6, 2011)

SUPPLEMENT (Filed With SEC on July 6, 2011)

WARRANT TO PURCHASE SHARES OF COMMON STOCK OF OCULUS INNOVATIVE SCIENCES, INC. (Void after November 30, 2018) (Filed With SEC on July 6, 2011)

AMENDMENT NO. 1 TO LOAN DOCUMENTS (Filed With SEC on July 6, 2011)

INTELLECTUAL PROPERTY SECURITY AGREEMENT (Filed With SEC on July 6, 2011)

AMENDMENT NO. 6 TO LEASE (Filed With SEC on June 3, 2011)

EXCLUSIVESALES AND DISTRIBUTION AGREEMENT (Filed With SEC on February 18, 2011)

EXCLUSIVECO-PROMOTION AGREEMENT (Filed With SEC on February 18, 2011)

PRODUCTOPTION AGREEMENT (Filed With SEC on February 18, 2011)

DISTRIBUTIONAGREEMENT (Filed With SEC on February 4, 2011)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on November 4, 2010)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on November 4, 2010)

PURCHASEAGREEMENT (Filed With SEC on November 4, 2010)

Exhibit10.1 CONTINUOUSOFFERING PROGRAM AGREEMENT (Filed With SEC on September 17, 2010)

AMENDMENTNO. 3 TO REVENUESHARING, PARTNERSHIP AND DISTRIBUTION AGREEMENT (Filed With SEC on August 5, 2010)

LOANAND SECURITY AGREEMENT Datedas of May 3, 2010 between OCULUSINNOVATIVE SCIENCES, INC., aDelaware corporation, asBorrower, and VENTURELENDING & LEASING V, INC., aMaryland... (Filed With SEC on May 6, 2010)

SUPPLEMENT tothe Loanand Security Agreement datedas of May 1, 2010 between OculusInnovative Sciences, Inc. (Borrower) and VentureLending & Leasing V, Inc. (Lender) (Filed With SEC on May 6, 2010)

WARRANTTO PURCHASE SHARES OFCOMMON STOCK OF OCULUSINNOVATIVE SCIENCES, INC. (Voidafter November 30, 2017) _______________________________________________ (Filed With SEC on May 6, 2010)

Common stock outstanding as of July 17, 2009 (Filed With SEC on July 21, 2009)

Common stock outstanding as of June 15, 2009 (Filed With SEC on July 9, 2009)

Common stock outstanding as of June 15, 2009 (Filed With SEC on June 17, 2009)

We may move forward into the pivotal phase of our U.S. clinical program for Microcyn Technology (Filed With SEC on June 11, 2009)

Common stock outstanding as of April 2, 2009 (Filed With SEC on April 10, 2009)

Entry Into a Material Definitive Agreement (Filed With SEC on February 27, 2009)

One hundred shares of our common stock, par value $0.0001 per share (Filed With SEC on February 9, 2009)

PURCHASE AGREEMENT (Filed With SEC on January 29, 2009)

REVENUE SHARING DISTRIBUTION AGREEMENT (Filed With SEC on January 29, 2009)

Current assets (Filed With SEC on August 6, 2008)

Complete a meeting with FDA regarding our Phase II results and pivotal trial protocols (Filed With SEC on June 13, 2008)

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT (Filed With SEC on March 28, 2008)

Securities Purchase Agreement, dated as of August 7, 2007 (Filed With SEC on August 13, 2007)

Initiate and complete Phase II trial for use of Microcyn in the treatment of infections in mildly infected diabetic foot ulcers (Filed With SEC on June 20, 2007)

Exhibit No (Filed With SEC on May 2, 2007)

Approval or Clearance Type (Filed With SEC on January 3, 2007)

Approval or Clearance Type (Filed With SEC on December 20, 2006)

Approval or Clearance Type (Filed With SEC on December 18, 2006)

Approval or Clearance Type (Filed With SEC on December 1, 2006)

Geographic Region (Filed With SEC on September 18, 2006)

many antiseptics, including Betadine, hydrogen peroxide and Dakins solution, are toxic, can destroy human cells and tissue, may cause allergic reactions and can impede the wound... (Filed With SEC on July 3, 2006)

Category

Industry

Companies

Contracts

Sonoma Pharmaceuticals, Inc. Contracts & Agreements